好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Severity of Tauopathy and Beta-amyloidosis in Logopenic Variant Primary Progressive Aphasia in Individuals With or Without a History of Developmental Dyslexia
Aging, Dementia, and Behavioral Neurology
N1 - Neuroscience in the Clinic: Innovations in Aphasia and Apraxia of Speech (4:00 PM-4:10 PM)
001

To assess differences in the severity of Alzheimer’s disease neuropathological changes in disease epicenters of patients with logopenic variant PPA (lvPPA) with a history of learning differences/developmental dyslexia (LD) versus lvPPA patients without such history (non-LD).

Learning differences and developmental dyslexia are overrepresented in the lvPPA population. It is not known whether a history of developmental differences is associated with a more severe phenotypic expression of Alzheimer’s disease pathology.

We quantified the cortical area fraction of phospho-tau immunohistochemistry (IHC) and beta-amyloid IHC in the angular gyrus and superior temporal gyrus of postmortem brains of 15 cases of lvPPA secondary to Alzheimer’s disease of which 9 non-LD cases (2 males and 7 females), and 6 LD cases (2 males and 4 females). Histological sections were digitally acquired, and foreground IHC-signal was automatically separated and thresholded to quantify the respective tau and beta-amyloid area fractions in each region.

There were no differences in the mean age at death between the two groups. Disease duration was longer in the LD group (10.7 ± 1.2 years) than in the non-LD group (8.1 ± 0.8 years), p=0.09. When corrected for sex, age at death and Apo E4 carrier status, the LD group showed higher tau pathology burden in the superior temporal gyrus compared to the non-LD group (0.91% ± 0.37, p = 0.03). No differences in tau pathology burden between the groups were observed in the angular gyrus (0.39% ±  0.41, p=0.37). There were no statistically significant differences in the area fraction of beta-amyloid between the two groups of patients in both the angular gyrus and the superior temporal gyrus.

Our data suggest that patients with lvPPA secondary to Alzheimer’s disease and a history of developmental differences have higher tau-pathology burden in the superior temporal gyrus compared to lvPPA-AD patients without such history.

Authors/Disclosures
Salvatore Spina, MD (UCSF Memory and Aging Center)
PRESENTER
Dr. Spina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Techspert.io. Dr. Spina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lumanity. Dr. Spina has received research support from Tau Consortium. Dr. Spina has received research support from Chan Zuckerberg Initiative, LLC. Dr. Spina has received research support from Bluefield Project to Cure FTD. Dr. Spina has received research support from NIH. Dr. Spina has received research support from Larry L. Hillblom Foundation. Dr. Spina has received personal compensation in the range of $500-$4,999 for serving as a Invited Speaker with Peking Union Medical Center Hospital.
Zachary Miller, MD (UCSF Memory and Aging Center) Dr. Miller has nothing to disclose.
Sevinc Jakab, PhD Dr. Jakab has nothing to disclose.
Margherita Tamagnini Miss Tamagnini has nothing to disclose.
MARIA LUISA MANDELLI, PhD Prof. MANDELLI has nothing to disclose.
Lisa Kritikos, NP Ms. Kritikos has nothing to disclose.
Hieu Pham Mr. Pham has nothing to disclose.
Siddarth Ramkrishnan Mr. Ramkrishnan has nothing to disclose.
Mia Lin Ms. Lin has nothing to disclose.
Jaeyeon Kim Dr. Kim has nothing to disclose.
Mercedes Paredes, MD, PhD (UCSF-Weill Institute of Neuroscience) Dr. Paredes has nothing to disclose.
Howard J. Rosen, MD (UCSF) Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Lea Grinberg Lea Grinberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen Inc. The institution of Lea Grinberg has received research support from NIH. The institution of Lea Grinberg has received research support from Eli Lilly. The institution of Lea Grinberg has received research support from BrightFouus. The institution of Lea Grinberg has received research support from Rainwater Charity Foundation.
William W. Seeley, MD Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Council. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global Consulting. Dr. Seeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BridgeBio. Dr. Seeley has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Seeley has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lyterian Therapeutics. The institution of Dr. Seeley has received research support from NIH. The institution of Dr. Seeley has received research support from Rainwater Charitable Foundation. The institution of Dr. Seeley has received research support from Bluefield Project to Cure FTD. The institution of Dr. Seeley has received research support from Chan-Zuckerberg Initiative.
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.
Maria Luisa Gorno Tempini, MD, PhD (UCSF Memory and Aging Center) The institution of Dr. Gorno Tempini has received research support from the NIH.